The Retention Rate and Safety of Secukinumab as a First-Line Biologic Agent in Axial Spondyloarthritis Compared to a First Tumor Necrosis Factor (TNF) Inhibitor: A Real-World, Longitudinal Study
S. Zemrani(Hôpital El Ayachi), R. Bahiri(Centre Hospitalier Universitaire de Rabat-Salé), Latifa Tahiri, I. El Binoune(Centre Hospitalier Ibn Sina), S. Rostom(Mohammed V University), F. Allali(Délégation Paris 5), Bouchra Amine(Hôpital El Ayachi)
Cited by 2
Related Papers
Why we should definitely include intra-articular hyaluronic acid as a therapeutic option in the management of knee osteoarthritis: Results of an extensive critical literature review
|Seminars in Arthritis and Rheumatism|2018|164
High Prevalence of Hypovitaminosis D in Morocco: Relationship to Lifestyle, Physical Performance, Bone Markers, and Bone Mineral Density
|Seminars in Arthritis and Rheumatism|2008|154
Increase in bone mineral density of patients with spondyloarthropathy treated with anti-tumour necrosis factor α
|Annals of the Rheumatic Diseases|2003|122
Sarcopenia in rheumatoid arthritis: prevalence, influence of disease activity and associated factors
|Rheumatology International|2017|114